Genmab — August 2018
-
Prøv lige at se omsætningen. Den er
minimal. -
Det er alene Nordea som er en større nettosælger med lidt over 5.000 stk.
-
Samme mønster vi har set næsten hver dag siden forrige mandag.
-
-
-
Nordea fordoblede nettosalget og A/B tog imod i auktionen.
-
Ja, de har rigtigt fået handlet med hinanden i dag!
-
Financial Performance First Half of 2018
Revenue was DKK 1,191 million in the first half of 2018 compared to DKK 1,024 million in the first half of 2017. The increase of DKK 167 million, or 16%, was mainly driven by the payment from Novartis of USD 50 million and higher DARZALEX royalties, partly offset by a decrease in DARZALEX milestones.
-
Operating expenses were DKK 732 million in the first half of 2018 compared to DKK 442 million in the first half of 2017. The increase of DKK 290 million, or 66%, was driven by the advancement of tisotumab vedotin, additional investments in our product pipeline, and the increase in employees to support expansion of our product pipeline.
-
Operating income was DKK 459 million in the first half of 2018 compared to DKK 582 million in the first half of 2017. The decrease of DKK 123 million, or 21%, was driven by increased operating expenses, which was partly offset by higher revenue.
-
Genmab is maintaining its 2018 financial guidance published on February 21, 2018.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind